Introduction {#Sec1}
============

Dysfunctioning of dopaminergic neurocircuitry has been implicated in various neuropsychiatric disorders including substance dependence, Tourette\'s syndrome, schizophrenia, and others (see (Kienast and Heinz [@CR28]) for a comprehensive review). Pharmacological challenge tests using dopamine receptor agonists provide a useful tool for investigating sensitivity of brain dopamine receptors. Classically, the release of growth hormone (GH) after administration of a dopamine agonist, e.g., apomorphine (APO) or bromocriptine has been used to assess central dopamine sensitivity, showing reduced plasma GH levels in patients suffering from alcohol dependence, major depression, and schizophrenia (Duval et al. [@CR14]; Mokrani et al. [@CR39]; Schmidt et al. [@CR45]).

The GH response to APO is mediated by dopamine receptors in the hindbrain (pituitary) region, whereas prefrontal and mesolimbic dopamine neurotransmission are more relevant for human behavior and neuropsychiatric disorders (Meister et al. [@CR38]; Seema0n and Van Tol [@CR46]). This report describes a dopamine challenge in healthy human volunteers, using three indices of dopamine function: plasma GH levels, performance on a continuous performance test, and prepulse inhibition of the acoustic startle response.

Dopamine is involved in cognitive functioning, including perceptual speed (spatial), working memory, and response inhibition (Backman et al. [@CR3]; Cropley et al. [@CR12]; Reeves et al. [@CR42]). Deficits in cognitive performance on various cognitive tasks have been described in disorders with a decrease in prefrontal dopamine functioning such as attention-deficit hyperactivity disorder (ADHD) and schizophrenia (Iversen and Iversen [@CR26]). Evidence from both animal and human studies, using pharmacological stimulation of dopamine receptors, suggests that both too little and too much stimulation of dopamine impairs cognitive performance (Cools [@CR11]; Gibbs and D\'Esposito [@CR22]; Vijayraghavan et al. [@CR57]).

Individuals with poor baseline performance on an n-back task, with presumed suboptimal prefrontal dopamine functioning, improved after administration of the dopamine agonist [D]{.smallcaps}-amphetamine, whereas individuals with high baseline performance deteriorated (Mattay et al. [@CR34]; Mattay et al. [@CR35]). Using the dopamine agonist bromocriptine, similar findings have been found on a variety of cognitive tasks including the Wisonsin Card Sorting Task (set shifting task), the Stroop task (interference task), and Corsi Block Tapping Task (spatial span task) (Kimberg et al. [@CR29]; Mehta et al. [@CR37]).

In addition, amphetamine improved performance on a continuous performance task in individuals scoring low on novelty seeking with presumed low levels of dopamine and impaired performance in individuals scoring high on novelty seeking with presumed high dopamine levels (Fleming et al. [@CR17]). Thus, a specific level of dopamine appears necessary for optimal functioning of the prefrontal cortex following an inverted U-dose-response curve (Gibbs and D\'Esposito [@CR22]; Swainson et al. [@CR48]; Vijayraghavan et al. [@CR57]; Zahrt et al. [@CR61]).

Administration of the dopamine agonist APO has been shown to disrupt performance on a working memory task in healthy human volunteers, probably by altered brain activity in the dorsolateral prefrontal cortex (Fletcher et al. [@CR18]; Friston et al. [@CR20]; Grasby et al. [@CR23]). We selected the AX continuous performance test (AX-CPT) because previous pharmacological studies with dopaminergic medication (apomorphine and cabergoline) have shown clear effects on task performance using this task (Frank and O\'Reilly [@CR19]; Schellekens et al. [@CR44]). We hypothesized that administration of APO to healthy controls would change task performance, depending on baseline task performance, such that performance improves in those subjects with low baseline performance and deteriorates in those with high baseline performance.

Prepulse inhibition (PPI), the phenomenon that a startle response elicited by a sudden intense stimulus (noise burst) is inhibited, when it is preceded by a weaker stimulus, has also been shown to be related to dopamine functioning. Reductions of PPI have been shown in disorders in which an increase in dopamine functioning has been hypothesized, such as schizophrenia, obsessive compulsive disorder, and tic disorder (see Braff et al. [@CR8] for a review on PPI paradigms in humans). Moreover, dopamine agonists have been shown to reduce PPI in animals and humans (see for further reviews: Braff et al. [@CR8], Swerdlow et al. [@CR49]; Swerdlow et al. [@CR51], [@CR53]). An inverted-U association between PPI levels and dopamine functioning has been hypothesized, since the disruptive effects of the dopamine agonist pergolide and amantadine on PPI in humans have been shown only in subjects with high baseline PPI levels, suggesting excessive dopaminergic stimulation in subjects with high levels of baseline PPI (Bitsios et al. [@CR5]; Talledo et al. [@CR54]).

Although the neuronal circuitry underlying PPI is extensive, there is a large amount of evidence indicating that the APO-induced deficit in PPI depends predominantly on stimulation of mesolimbic dopamine receptors in the nucleus accumbens (Swerdlow et al. [@CR49]; Swerdlow et al. [@CR51], [@CR53]). We expected administration of APO to change PPI, depending on baseline levels of PPI, such that PPI increases in those subjects with low baseline PPI and reduces in those with high baseline PPI.

The relationship between APO levels in blood, brain, and GH release was first explored by Aymard et al. ([@CR2]). They showed that APO levels in the second compartment (i.e., the concentration of APO in cerebrospinal fluid; CSF), correlated better with plasma GH levels than APO levels in the first compartment (i.e., the concentration of APO in plasma) (Aymard et al. [@CR2]; Hofstee et al. [@CR25]). As shown by Hofstee et al. ([@CR25]), APO levels in CSF can be reliably calculated from plasma APO concentrations using pharmacokinetic modeling (Hofstee et al. [@CR25]). We measured plasma APO levels and calculated APO levels in the CSF and hypothesized that central effects of APO can best be modeled using calculated APO levels in the CSF compared to observed APO levels in the plasma. We used both subcutaneous (s.c.) and sublingual (s.l.) administration of APO in order to be able to model the central effect of APO in different kinetic profiles and to assess which mode of administration was most appropriate for use in a challenge test.

Methods and materials {#Sec2}
=====================

Design {#Sec3}
------

A double-blind, placebo-controlled challenge study was performed in 15 healthy males using a balanced, cross-over design with three treatment conditions in a double-dummy approach: APO 2 mg s.l./placebo s.c., APO 0.005 mg/kg s.c./placebo s.l., and placebo s.l./s.c.. Low doses of APO were used because of poor tolerability at higher doses (nausea, vomiting, and collapse, unpublished pilot studies). The study protocol was approved by the regional ethical board.

Participants {#Sec4}
------------

Participants were recruited through advertisements in regional newspapers and at the campus of Radboud University Nijmegen. After written informed consent, participants were screened for any medical condition, including laboratory abnormalities and the use of medication or drugs within 2 months prior to the study. Auditory acuity was evaluated during medical examination by use of tuning fork tests (Weber, Rinne, and Swabach) and whisper tests.

Psychiatric history was assessed using the Dutch version of the Mini International Neuropsychiatric Interview for psychiatric disorders version 2.1 and the Dutch version of the ADHD rating scale (Sandra Kooij et al. [@CR43]; Sheehan et al. [@CR47]; van Vliet and de Beurs [@CR56]). To assess history of drug and alcohol use, we used the Dutch version of the Addiction Severity Index, Section 4 (Langeland et al. [@CR31]; McLellan et al. [@CR36]). Participants with any psychiatric (family) history including substance use disorders and habitual smoking (daily nicotine use) were excluded. Out of 16 screened individuals, 15 were eligible, mean age (SD) 25.2 (5.9) years. Participants were not allowed to smoke or use caffeine during study mornings, or take alcohol 2 days before study days.

Measurements {#Sec5}
------------

### Plasma apomorphine and growth hormone levels {#Sec6}

To assess plasma APO and GH levels, blood (4 ml) was taken. After centrifugation, 2.0-ml samples were kept on ice and stored at −30˚C. APO levels were assessed by high-pressure liquid chromatography with electrochemical detection (Essink et al. [@CR16]). GH levels were assessed by radio immuno assay, using antiserum raised in guinea pig. The first (80/505) international standard for GH was used for the standard curve with a detection limit of 1.6 mIU/L.

Two participants with baseline GH levels \>10 U/l were excluded from analysis. Plasma APO levels were available for nine of 15 individuals due to contamination of the antioxidant in one series of batches.

### AX continuous performance task {#Sec7}

In the AX continuous performance task (AX-CPT), single white letters were consecutively shown on a black screen (interstimulus interval = 1,300 ms). Participants were instructed to give a target response (right button press) after the probe \"X\", if preceded by a cue \"A\", or a non-target response (left button press) after any other combination of letters (van der Linden et al. [@CR55]). To increase task difficulty, two distracter letters were presented between cue and probe (van der Linden et al. [@CR55]). To increase sensitivity for impulsive response styles (commission errors), 70% were target trials (Braver et al. [@CR9]). Responses were scored in a window between 100 and 2,000 ms after stimulus onset. Performance during each session was calculated as the mean reaction time and accuracy on AX trials (the percentage commission errors). Non responses (omissions) were not taken into account given the low number (\<1%). A median split on baseline accuracy was used to divide high and low baseline performers (Kimberg et al. [@CR29]).

### Prepulse inhibition {#Sec8}

Reflex eyeblink responses were measured as electromyographic activity over the right orbicularis oculi muscle with a sampling frequency of 1,000 Hz (van der Linden et al. [@CR55]). Background sound consisted of 70 dB white noise pulse-alone trials of 105 dB and white noise bursts with instant rise time. Prepulse trials consisted of either 75 or 85 dB white noise bursts preceding 105 dB pulses. Pulse duration was 20 ms for prepulses and 40 ms for startle pulses. Interstimulus interval was 100 ms, intertrial intervals ranged between 8-12 s randomly. Each PPI measurement started with 15 habituation trials (105 dB PA trials) that were subsequently excluded from the analysis followed by 12 trials of each type (105 dB, 85/105 dB, 75/105 dB) in a pseudo-random order.

Data cleaning was performed off-line with MIDAC software (test organizer-MIDAC polygraphy module, Instrumentation Service, UMC St Radboud, Nijmegen, The Netherlands), with a response window from 20-150 ms after stimulus onset. Startle responses with an inconstant baseline 20 ms before the stimulus with a response to the prepulse or trials in which no startle response was detected were excluded from further calculations.

The average amplitude of startle responses was calculated for each trial type (105 dB, 75/105 dB and 85/105 dB) per startle session (i.e., six sessions per treatment condition). Percentage PPI was calculated for 75/105 dB and 85/105 dB trials, per startle session, as follows: $\documentclass[12pt]{minimal}
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\begin{document}$$ \left[ {\left( {{M_{\text{amplitude PA}}} - {M_{\text{amplitude PP}}}} \right)/\left( {{M_{\text{amplitude PA}}}} \right)} \right]*{\text{1}}00\% $$\end{document}$. A median split on baseline PPI (both 75/105 dB and 85/105 dB) was used to divide high and low baseline sensorimotor gaters (Bitsios et al. [@CR5]; Talledo et al. [@CR54]).

Procedure {#Sec9}
---------

Study mornings started at 8:30 a.m. with a standardized light breakfast. Measurements were performed, once before and five times after drug administration, starting with blood sampling, followed by a 9-min startle session and, consecutively, 10-min AX-CPT, each cycle lasting 20 min (Fig. [1](#Fig1){ref-type="fig"}). Treatment conditions were 10 to 25 days apart. Fig. 1Outline of study days

Data analysis {#Sec10}
-------------

Statistical Package for the Social Sciences (version 16.0) under Windows was used for statistical analysis, with α set at.05 (two-sided). The effect of APO on GH, performance on the CPT-AX, and acoustic startle was analyzed using GLM repeated measures analysis of variance, with treatment (APO s.l., APO s.c., and placebo) and time (baseline, T1, T2, T3, T4, and T5) as within-subject factors. Scores on each outcome measure at baseline were used to divide subjects by median split into low and high performers so that we could examine the effect of APO on these two groups for each outcome measure a with group as a between-subject factor. In order to control for a learning effect over the different sessions, order was entered as a between-subjects factor in the analysis of the AX-CPT. Since both the factors, time and treatment, have two or more degrees of freedom, Greenhouse-Geisser correction was used, epsilon values and adjusted *p* values are reported.

In order to identify the specific time points with the largest effect of APO, simple contrasts to baseline were analyzed post hoc, only when the omnibus test showed a significant interaction effect. To assess the relation between baseline task performance on the AX-CPT and baseline PPI, we computed Pearson\'s correlation between speed and accuracy on the AX-CPT and PPI on 75/105 and 85/105 dB.

Individual curves of APO levels in the first and second compartment were fitted in a previously validated algorithm in MW/Pharm, a software package developed to study the clinical effect of APO, e.g., in patients suffering from Parkinson\'s disease (Mediware, version 3.60; Hofstee et al. [@CR25]; Neef et al. [@CR40]; Neef and van Laar [@CR41]). Individual fits were based on plasma APO levels, individual pharmacokinetic parameters (volume of distribution, rate constants for elimination and intercompartmental exchange, renal function, and body mass index), and population kinetics. We computed Pearson\'s correlations between the central outcome measures and time-locked APO levels both in the first and second compartment (plasma and CSF).

Results {#Sec11}
=======

Plasma apomorphine and growth hormone levels {#Sec12}
--------------------------------------------

Both s.c.- and s.l.-administered APO resulted in detectable plasma APO levels (Fig. [2](#Fig2){ref-type="fig"}). GH levels increased after administration of APO, see Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"} (F (10, 12) = 8.4, *p* \< .001). Post hoc analysis showed that the effect of APO was mainly at 50 min after s.c. administration (F (1, 12) = 18.3, *p* = .001). Fig. 2Results: plasma apomorphine (APO) concentration and APO levels as estimated in the second compartment after oral (2 mg) and sublingual (0.005 mg/kg) administrationTable 1Results: baseline values and effect of treatment with apomorphine (APO) on plasma growth hormone (GH) levels, performance on the AX-continuous performance task (AX-CPT), and prepulse inhibition (PPI)Outcome measureMean at baseline (SD)F-Statistic (df)ε-value*p* valueGH*NA* -Time13.4 (1.8, 12).36\<.001 -Treatment10.9 (1.7, 12).87.001 -Time\*treatment8.4 (2.7, 12).27\<.001CPT-AX, reaction time (msec)347.91 ms (66.61) -Time2.1 (3.3, 14).67.107 -Treatment2.7 (1.9, 14).96.090 -Time\*treatment1.7 (4.2, 14).42.157 -Time\*treatment\*baseline2.9 (4.2, 14).030CPT-AX, commission errors (%)4.8% (5.4) -Time1.0 (3.3, 14).67.399 -Treatment0.4 (1.4, 14).71.580 -Time\*treatment0.5 (3.2, 14).32.675 -Time\*treatment\*baseline3.5 (3.2, 14).030PPI 75/105 dB (%)9.7% (22.6) -Time1.1 (3.7,14).73.381 -Treatment2.2 (1.6,14).78.143 -Time\*treatment1.7 (5.0,14).50.161 -Time\*treatment\*baseline2.8 (5.0,14).024PPI 85/105 dB (%)22.2% (24.6) -Time2.5 (3.5, 14).70.040 -Treatment3.5 (1.5,14).75.050 -Time\*treatment1.5 (4.9, 14).49.154 -Time\*treatment\*baseline1.4 (4.9, 14).182*Time* main effect of time, *treatment* main effect of treatment, *Time\*treatment* time by treatment interaction effect, *Time\*treatment\*baseline* time by treatment by baseline performance interaction effectFig. 3Results: plasma growth hormone levels before and after sublingual (2 mg) and subcutaneous (0.005 mg/kg) administration of apomorphine (APO)

AX continuous performance task {#Sec13}
------------------------------

Baseline task performance did not differ between treatments (commission errors: F (2, 14) = 0.6, *p* = .547; reaction time: F (2, 14) \<.01, *p* = .977). There was no effect of order on task performance (F (3.3, 14) = .6, *p* = .611). There was no difference in age or APO levels between the median split groups (see Supplementary Table [1](#MOESM1){ref-type="supplementary-material"}a). The percentage commission errors increased after APO, particularly in subjects with more error responses at baseline, see Table [1](#Tab1){ref-type="table"} and Fig. [4a](#Fig4){ref-type="fig"} (F (3.2, 14) = 3.5, *p* = .030). Mean reaction time on AX-trials increased after APO in subjects with slow baseline responses, see Table [1](#Tab1){ref-type="table"} and Fig. [4b](#Fig4){ref-type="fig"} (F (4.2, 14) = 2.9, *p* = .030). Fig. 4Results: performance on AX-continuous performance task (CPT-AX) before and after sublingual (2 mg) and subcutaneous (0.005 mg/kg) administration of apomorphine (APO). **a** Percentage commission errors on CPT-AX by baseline task performance. **b** Reaction time on CPT-AX by baseline task performance

Post hoc analysis showed that the effect of APO on both error percentage and reaction time was mainly at 40 min after s.c. administration (error percentage: F (1, 14) = 38.1, *p* \< .001, reaction time: F (1, 14) = 21.6, *p* = .001).

Prepulse inhibition {#Sec14}
-------------------

The number of excluded trials increased between baseline and T5; from 13% to 26% for 75/105 dB (F (5, 14) = 4.7, *p* = .001), from 35% to 48% 105 dB (F (5, 14) = 4.8, *p* = .001), and from 24% to 32% 85/105 dB (F (5, 14) = 3.0, *p* = .018). This is mainly caused by an increase in the number of non responses. The number of excluded trials did not differ over the three drug conditions (105 dB trials: F (10, 14) = 1.1, *p* = .331, 75/105 dB trials: F (10, 14) = 0.5, *p* = .853, 85/105 dB trials: F (10, 14) = 0.5, *p* = .900) indicating no difference in habituation to the startle stimulus over all treatment conditions. For the results of the analysis on startle amplitudes (see Supplementary Table [2](#MOESM2){ref-type="supplementary-material"} and Supplementary Figs. [1](#MOESM3){ref-type="supplementary-material"}a--c).

Baseline PPI did not differ between treatments (PPI 75/105 dB: F (2, 14) = 0.4, *p* = .686, PPI 85/105 dB: F (2, 14) \< 0.1, *p* = .911). There was no difference in age or APO levels between the median split groups (see Supplementary Table [1](#MOESM1){ref-type="supplementary-material"}b). PPI decreased after administration of APO for high-intensity prepulse trials (85/105 dB), see Table [1](#Tab1){ref-type="table"} and Fig. [5a](#Fig5){ref-type="fig"} (F (1.5, 14) = 3.5, *p* = .050). Baseline PPI did not modulate the effect of APO on PPI in high-intensity prepulse trials (F (4.9, 14) = 1.4, *p* = .182). PPI increased after administration of APO for low intensity prepulse trials (75/105 dB) in subjects with low baseline PPI, see Table [1](#Tab1){ref-type="table"} and Fig. [5b](#Fig5){ref-type="fig"} (F (5.0, 14) = 2.8, *p* = .024). Fig. 5Results: percentage prepulse inhibition (PPI) before and after sublingual (2 mg) and subcutaneous (0.005 mg/kg) administration of apomorphine (APO) on 75 dB and 85 dB prepulse trials. **a** Percentage PPI on 75 dB prepulse trials by high vs. low baseline levels of PPI. **b** Percentage PPI on 85 dB prepulse trials

Post hoc analysis showed that the effect of APO on PPI was mainly at 30 min after s.c. administration (85/105 dB: F (1, 14) = 6.0, *p* = .030; 75/105 dB: F (1, 14) = 10.1, *p* = .008).

Baseline PPI levels for low intensity prepulse trials were inversely correlated with baseline accuracy on task performance (75/105 dB: R = −.59, *p* = .021).

Pharmacokinetic/Pharmacodynamic analysis {#Sec15}
----------------------------------------

The effect of APO on the outcome measures showed close resemblance with the kinetics of APO (Fig. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}). The relation between APO levels and the observed effects could best be modeled using S-curves (Fig. [6](#Fig6){ref-type="fig"}). Central measures correlated best with APO levels in the second compartment after s.c. administration, GH levels, and accuracy on the AX-CPT in particular (Table [2](#Tab2){ref-type="table"}). Fig. 6Results: relation between apomorphine (APO) levels in the first and second compartment (blood and brain) and time-locked plasma growth hormone (GH) levels and error percentage on the AX-continuous performance task (AX-CPT). **a** GH after 0.005 mg/kg APO s.c. **b** Error percentage on AX-CPT after 0.005 mg/kg APO s.l.Table 2Mean correlations between central outcome measures (plasma GH levels and performance on the AX-continuous performance task (CPT-AX)) and apomorphine (APO) levels in plasma as calculated in the second compartmentGH, mean R (SD)AX-CPT, mean R (SD) reaction time errorsPPI, mean R (SD) 75/105 dB 85/105 dBAPO 0.005 mg/kg s.c.*N* = 8*N* = 9*N* = 9*N* = 9*N* = 9 1st compartment0.20 (0.30)0.41 (0.48)0.58 (0.37).289 (.25)−.175 (.44) 2nd compartment0.58 (0.20)0.45 (0.44)0.58 (0.37).282 (.35)−.178 (.39)APO 2 mg s.l.*N* = 5*N* = 5*N* = 5*N* = 5*N* = 5 1st compartment0.01 (0.27)0.46 (0.43)0.33 (0.37).074 (.41)−.192 (.33) 2nd compartment0.30 (0.41)0.43 (0.43)0.46 (0.36).137 (.22)−.373 (.32)

Adverse events {#Sec16}
--------------

Nausea was reported by five participants, between 10 and 40 min, only after s.c. administration of APO. Yawning and weariness were reported in all conditions (placebo: seven participants, APO s.l. ten participants, and APO s.c. 12 participants).

Discussion {#Sec17}
==========

Administration of the direct dopamine receptor agonist APO to healthy individuals resulted in increased plasma GH levels and disrupted performance on the AX-CPT as predicted. APO improved PPI in prepulse trials of low intensity (75/105 dB) in subjects with poor baseline sensorimotor gating and disrupted PPI in high-intensity prepulse trials (85/105 dB).

Elevated levels of plasma GH after administration of APO are in line with previous studies that have shown GH responses after comparable doses of APO in healthy controls and patients suffering from schizophrenia, major depression, and alcohol dependence (Schmidt et al. [@CR45]). The dose of APO currently administered appears to be sufficient to stimulate central dopamine receptors.

The observed deterioration in cognitive performance after APO is in line with other studies, showing decreased cognitive performance after administration of APO and the dopamine agonist pramipexole (Hamidovic et al. [@CR24]; Schellekens et al. [@CR44]). Since dopamine receptors in the prefrontal cortex (PFC) are located both at the presynaptic and postsynaptic neuron, one could speculate that the disruptive effect on cognitive performance is caused by decreased dopamine functioning after stimulation of presynaptic dopamine receptors or excessive dopamine functioning after stimulation of postsynaptic dopamine receptors (al-Tikriti et al. [@CR1]; Wang and Pickel [@CR59]).

In contrast with the hypotheses, participants with poor baseline cognitive performance were most sensitive to the deteriorating effects of APO on cognitive performance. That individuals with presumed lower levels of prefrontal dopamine functioning are more sensitive to the detrimental effects of APO on cognitive performance suggests that stimulation of presynaptic dopamine receptors, and subsequently reduced dopamine neurotransmission in the PFC is involved. Further studies are needed to explore the mechanisms underlying the effect of APO on cognitive performance.

The observation of PPI disruption in high-intensity prepulse trials after administration of APO, versus PPI enhancement in low intensity prepulse trials, is in line with previous findings with the dopamine agonists pergolide and 4-propyl-9-hydroxynaphthoxazine in rats (Martin-Iverson and Else [@CR33]; Swerdlow et al. [@CR51], [@CR53]). This paradoxical finding has been hypothesized to result from either agonist action on dopamine receptors located pre and post synaptically, or at different parts in the startle neurocircuitry, or from agonist action on different neurochemical subclasses of dopamine receptors, e.g., D3 and D4 (Martin-Iverson and Else [@CR33]; Swerdlow et al. [@CR53]).

Although dopamine receptors are located in several different brain areas, there is substantial evidence from preclinical research suggesting that the final pathway in the disruptive effect of APO on PPI is dependent on stimulation of dopamine receptors in the nucleus accumbens. Local application of dopamine agonists in the nucleus accumbens, but not in the neostriatum or the orbitofrontal cortex, reduces PPI (Swerdlow et al. [@CR50]; Wan et al. [@CR58]). Interestingly, within the prefrontal cortex, dopamine antagonists rather than agonists appear to decrease PPI (Ellenbroek et al. [@CR15]; Zavitsanou et al. [@CR62]). More importantly, Swerdlow and colleagues also showed that the PPI disruptive effect of systemically applied dopamine agonists can be blocked by blocking dopamine transmission in the nucleus accumbens (Swerdlow et al. [@CR52]). These data suggest that the effects of dopamine agonists on PPI are predominantly mediated via the mesolimbic, nucleus accumbens, and dopamine receptors. However, it cannot be ruled out that the disruptive effect of APO on PPI may be mediated by dopamine receptors in the medial prefrontal cortex (Broersen et al. [@CR10]; Lacroix et al. [@CR30]).

At low prepulse intensities, APO-improved sensorimotor gating in participants with suboptimal baseline levels of PPI with presumed suboptimal mesolimbic dopamine functioning. This suggests that stimulation of postsynaptic dopamine receptors and subsequently increased mesolimbic dopamine neurotransmission is involved. In contrast, baseline levels of PPI did not modify the response to APO in high-intensity prepulse trials. PPI on high-intensity prepulse trials is rather robust and likely less sensitive to the effect of baseline PPI on APO sensitivity. Yet, at low prepulse intensities, PPI may be dependent on a more narrow optimum of mesolimbic dopamine functioning.

The observed negative correlation between baseline cognitive performance and baseline PPI on low intensity prepulse trials supports a previously suggested reciprocal relation between prefrontal and subcortical dopamine neurotransmission (Kellendonk et al. [@CR27]; Wilkinson [@CR60]). Participants with high baseline cognitive performance, i.e., presumed optimal prefrontal dopamine functioning showed impaired levels of sensorimotor gating, i.e., presumed suboptimal mesolimbic dopamine functioning. Moreover, subjects sensitive to deteriorating effects of APO on cognitive performance appeared to be less sensitive to the PPI enhancing effects of APO. This again supports the idea that whereas cognitive performance is more related to cortical dopaminergic systems, PPI is more mediated via mesolimbic dopaminergic systems.

Yet, it has previously been suggested that sensorimotor gating is a pre-attentional function, important for the integrity of higher order cognitive processes (Braff and Geyer [@CR6]). Previous studies have indeed shown levels of PPI to correlate with attention and planning ability (Bitsios and Giakoumaki [@CR4]; Csomor et al. [@CR13]; Giakoumaki et al. [@CR21]). These findings merit further investigation with respect to the relation between sensorimotor gating and higher order cognitive processes.

Several additional issues regarding PPI need to be considered. First, the number of excluded startle trials in this study (20%) is high compared to literature (5%) (Bitsios et al. [@CR5]; Braff et al. [@CR7]; Liechti et al. [@CR32]; van der Linden et al. [@CR55]). Moreover, the number of excluded trials increased over consecutive startle sessions. This may result from both habituation and weariness of the participants due to repeated measurement sessions. Though there was no effect of treatment on the number of excluded trials, habituation effects may have influenced the observed effects of APO on PPI. Importantly, we used a low dose of APO (0.005 mg/kg s.c. or 2 mg s.l.) compared to animal literature (e.g., 0.5 mg/kg). Direct translation of the current findings to animal findings is, therefore, limited.

The effect of APO on the central outcome measures closely follows the kinetics of APO. In line with our hypotheses, we found the best correlation between central outcome measures and calculated APO levels in the second compartment (CSF) after s.c. administration. APO levels in the second compartment show an S-curve relation with central outcome measures, whereas plasma APO concentrations (first compartment) show a poor correlation due to a large counter-clock hysteresis curve. The use of two-compartmental pharmacokinetic/pharmacodynamic (PK/PD) modeling may provide further insight in true pharmacodynamic differences in dopamine receptor sensitivity between groups taking into account pharmacokinetic differences. Since correlation coefficients were rather low, factors other than APO levels may contribute to the observed changes in central outcome measures like weariness, motivational decline, habituation to the acoustic startle, and a learning effect on the AX-CPT. In addition, PK/PD analyses were based on a limited number of participants. Future studies are needed to confirm the current findings.

Conclusions {#Sec18}
===========

The apomorphine challenge test appears a useful tool to assess dopamine receptor functioning at the level of the forebrain. Baseline performance modulated the effect of APO on task performance and PPI. This may be explained by the hypothesized inverted U-shape relation between prefrontal dopamine functioning and cognitive performance and mesolimbic dopamine functioning and sensorimotor gating. The current findings also suggest a reciprocal relation between prefrontal and mesolimbic dopamine functioning.

More studies on the relation between the central effects of APO and levels of APO in the CSF are needed. Future APO challenge studies into dopamine dysfunctioning in neuropsychiatric disorders preferably use multiple outcome measures after s.c. administration.
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